###begin article-title 0
###xml 52 60 <span type="species:ncbi:9606">patients</span>
Thrombophilic screening in retinal artery occlusion patients
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
Retinal artery occlusion (RAO) is an ischemic vascular damage of the retina, which frequently leads to sudden, mostly irreversible loss of vision. In this study, blood thrombophilic factors as well as cardiovascular risk factors were investigated for their relevance to this pathology. Thrombophilic risk factors so far not evaluated were included in the study.
###end p 2
###begin title 3
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and methods
###end title 3
###begin p 4
###xml 7 15 <span type="species:ncbi:9606">patients</span>
28 RAO patients and 81 matched control subjects were examined. From blood samples, protein C, protein S, antithrombinopathy, and factor V (Leiden) mutation (FV), factor II gene polymorphism, factor VIIIC level, plasminogen activity, lipoprotein(a) and fibrinogen levels, hyperhomocysteinemia and presence of anticardiolipin - antiphospholipid antibodies were investigated. Possibly relevant pathologies such as diabetes mellitus, hypertension, and ischemic heart disease were also registered. Statistical analysis by logistic regression was performed with 95% confidence intervals.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 99 100 99 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 250 251 250 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 332 333 332 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 16 24 <span type="species:ncbi:9606">patients</span>
In the group of patients with RAO only the incidence of hypertension (OR: 3.33, 95% CI: 1.30-9.70, p = 0.014) as an average risk factor showed significant difference, but thrombophilic factors such as hyperfibrinogenemia (OR: 2.9, 95% CI: 1.29-6.57, p = 0.010) and the presence of FV (Leiden mutation) (OR: 3.9, 95% CI: 1.43-10.96, p = 0.008) increased the chances of developing this disease.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
Our results support the assumption that thrombophilia may contribute to the development of RAO besides vascular damage due to the presence of cardiovascular risk factors. Further studies are needed, however, to justify the possible use of secondary prophylaxis in form of anticoagulant/antiplatelet therapy.
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
###xml 0 17 0 17 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13-co-2-557">Von Graefe (1859)</xref>
###xml 116 119 <span type="species:ncbi:9606">man</span>
Von Graefe (1859) was the first to describe the classic clinical picture of retinal artery occlusion. He observed a man who had experienced a sudden loss of vision in the right eye with the following fundus findings: pale disk, attenuated arteries and veins, and cloudy retina that produced a macular cherry-red spot.
###end p 10
###begin p 11
###xml 378 396 378 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2-co-2-557">Bertram et al 1995</xref>
###xml 398 416 398 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1-co-2-557">Ben-Ami et al 2002</xref>
###xml 418 435 418 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3-co-2-557">Cahill et al 2003</xref>
###xml 437 452 437 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4-co-2-557">Chua et al 2006</xref>
###xml 200 208 <span type="species:ncbi:9606">patients</span>
Clinicians usually differentiate acute retinal arterial occlusion (RAO), such as central retinal artery occlusion (CRAO) and branch retinal artery occlusion (BRAO). Fundoscopy characteristics of CRAO patients are the pale, ischemic retinal edema with a cherry red spot in the macula, and arteriolar narrowing or slugging with retinal arterioles irregularities in their caliber (Bertram et al 1995; Ben-Ami et al 2002; Cahill et al 2003; Chua et al 2006).
###end p 11
###begin p 12
Fundus changes of BRAO are white, ischemic retina in the area supplied by an obstructed artery. In addition, capillary changes have also been described.
###end p 12
###begin p 13
###xml 206 223 206 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7-co-2-557">M&#252;ller et al 1992</xref>
###xml 225 242 225 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15-co-2-557">Wenzel et al 1993</xref>
###xml 244 262 244 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2-co-2-557">Bertram et al 1995</xref>
###xml 264 282 264 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6-co-2-557">Geigner et al 1999</xref>
###xml 284 301 284 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8-co-2-557">Pianka et al 2000</xref>
###xml 323 341 323 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1-co-2-557">Ben-Ami et al 2002</xref>
###xml 343 359 343 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14-co-2-557">Weger et al 2003</xref>
###xml 361 382 361 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12-co-2-557">Stojakovic et al 2007</xref>
RAO is a multifactorial disorder. Next to the role of cardiovascular risk factors, thrombophilic factors have also been shown to play a role. The exact etiology and pathogenesis for RAO is still not clear (Muller et al 1992; Wenzel et al 1993; Bertram et al 1995; Geigner et al 1999; Pianka et al 2000; Saloman et al 2001; Ben-Ami et al 2002; Weger et al 2003; Stojakovic et al 2007). This is one of the reasons why targeted therapy for RAO is not available.
###end p 13
###begin p 14
###xml 205 222 205 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7-co-2-557">M&#252;ller et al 1992</xref>
###xml 224 242 224 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6-co-2-557">Geigner et al 1999</xref>
###xml 244 261 244 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8-co-2-557">Pianka et al 2000</xref>
Our study investigated the pathogenetic factors from the widely accepted, so-called "acquired" cardiovascular risk factors (hypertension, hypercholesterolemia) in parallel with thrombophilic risk factors (Muller et al 1992; Geigner et al 1999; Pianka et al 2000). We predict that our knowledge of the pathogenetic risk factors of RAO may enable us to define therapy and secondary prophylaxis as well.
###end p 14
###begin title 15
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and methods
###end title 15
###begin p 16
###xml 52 60 <span type="species:ncbi:9606">patients</span>
###xml 228 236 <span type="species:ncbi:9606">patients</span>
Between 1997 and January of 2006, we studied 28 RAO patients and 81 age- and sex-matched control subjects in our Department of Ophthalmology within the Division of Rare Diseases. The mean age was 61.1 (+/-12.3) years in the RAO patients and 61.6 (+/-12.6) years the control subjects. The inclusion criteria for RAO were: sudden, painless loss of vision, presence of relative afferent pupillary defects, characteristic visual field defects, and fundus changes. The following fundoscopic findings were recorded: pale, ischemic retinal edema with a cherry red spot in the macula, and arteriolar narrowing or slugging with retinal arterioles irregularities in their caliber. Whenever the above changes were detected in all the four arterioles' branches we referred to it as central occlusion (CRAO), and if one arteriole area was seen, the branch occlusion (BRAO) was established.
###end p 16
###begin p 17
###xml 23 31 <span type="species:ncbi:9606">patients</span>
###xml 298 301 <span type="species:ncbi:9606">men</span>
###xml 306 311 <span type="species:ncbi:9606">women</span>
Exclusion criteria for patients with RAO comprised malignancy and vasculitis. To exclude vasculitis, the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels were determined. The possibility of vasculitis was considered when the ESR level was higher than 33 mm/h and 35 mm/h in men and women, respectively, or when the CRP was higher than 0.5 mmol/l. We examined the presence of general symptoms such as headache, muscle ache, other, etc.
###end p 17
###begin p 18
###xml 55 63 <span type="species:ncbi:9606">patients</span>
###xml 272 280 <span type="species:ncbi:9606">patients</span>
###xml 324 332 <span type="species:ncbi:9606">patients</span>
###xml 514 522 <span type="species:ncbi:9606">patients</span>
###xml 578 586 <span type="species:ncbi:9606">patients</span>
###xml 822 830 <span type="species:ncbi:9606">Patients</span>
The control group consisted of 81 age- and sex-matched patients who have previously undergone cataract surgery, and subsequently presented retinal vascular diseases. In this case, at least one year had passed between the cataract surgery and the follow-up examination. No patients had suffered from autoimmune diseases. All patients were given detailed description of the main points of the examination, to which they then gave their written consent. We registered the previous diseases and medical therapy of our patients prior to their first ophthalmologic examination. Those patients who were considered hypertensive, in that an internal medicine specialist had diagnosed them based on a measurement of higher than 140/90 mmHg on several occasions, also received scheduled controls as well as antihypertensive therapy. Patients suffering from hypercholesterolemia (above 5.2 mmol/l) or hypertriglyceridemia (above 1.2 mmol/l) took part in oral antihyperlipidemic therapy.
###end p 18
###begin p 19
###xml 8 16 <span type="species:ncbi:9606">patients</span>
All the patients control groups were subjected to a complete ophthalmologic examination, including best corrected visual acuity, a visual field test using Goldmann perimetry when visual acuity allowed it, intraocular pressure measurement using Goldmann applanation tonometry, slit lamp biomicroscopy and fundoscopy, as well as fluorescein angiography.
###end p 19
###begin p 20
###xml 114 121 <span type="species:ncbi:9606">patient</span>
The risk factors (hypertension, diabetes mellitus, ischemic heart disease, arteriosclerosis, and smoking) of each patient were also documented. In addition to the routine laboratory investigations, the level of serum cholesterol and triglyceride were measured, and an hemostasis screening test (prothrombin time, thrombin time, activated partial thromboplastin time) was performed. The starting date of the first ophthalmologic symptoms was noted and six weeks later the blood samples were taken to evaluate thrombophilic risk factors: protein C (PC) and protein S (PS) levels, antithrombinopathy (AT), activated protein-C (APC) resistance and Leiden mutation, presence of FII G20210A allele, fibrinogen level, anticardiolipin - antiphospholipid (ACL-APL) antibodies, elevated levels of factor VIII (FVIII), plasminogen, and lipoprotein-a (Lp(a)). The level of FVIII was considered elevated only when it increased in three consecutive measurements, made at 6-week intervals after the initial screening. This way, we could filter out the false positive results. Since FVIII also plays a role as an acute phase protein, elevated levels can be found in the acute RAO phase without actually having any pathological role. We have followed the same protocol for the determination of decreased levels of PC, PS, and AT.
###end p 20
###begin p 21
###xml 164 172 <span type="species:ncbi:9606">patients</span>
Control examinations were dated 6 weeks, 3 to 6 months, and one year after the initial examination. The total follow up time was between 11 months to 9 years. Nine patients were followed over a 9 year period.
###end p 21
###begin title 22
Laboratory methods
###end title 22
###begin p 23
All laboratory analysis was performed at the Department of Clinical Biochemistry and Molecular Pathology, University of Debrecen Medical and Health Science Center, Debrecen, Hungary.
###end p 23
###begin p 24
###xml 256 267 256 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5-co-2-557">Clauss 1957</xref>
###xml 694 723 694 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2-co-2-557">Bertram and colleagues (1995)</xref>
Determinations of lipid (triglyceride, cholesterol) levels were performed using the enzymatic colorimetric method in a P800 modular chemical analyzer (Roche Diagnostics, Mannheim, Germany). Fibrinogen levels were determined according to the Clauss method (Clauss 1957). PC and PS activities were measured using coagulation tests (Diagnostica Stago). AT and plasminogen were determined by chromogenic assays (Diagnostica Stago). FVIII was determined using a clotting assay. All these determinations were performed in an STA-Compact coagulometer (Diagnostica Stago). FV Leiden mutation and FII G20210A allele were detected using a real-time polymerase chain reaction (RT-PCR) method according to Bertram and colleagues (1995).
###end p 24
###begin p 25
Determination of the activated protein-C (APC-R) ratio was achieved by the measurement of two different activated partial thromboplastin time (APTT). One measurement represented the plasma with APC, the other one without APC. The APC ratio is the ratio between these two measurements, which we have considered positive at the level of 2 or higher. In positive cases, the existence of the Leiden-mutation is always justified by molecular genetic methods. The potentially abnormal DNA sequences were amplified by polymerase chain reaction (PCR). The PCR products were digested with restriction endonuclease (MnII), and the restriction fragments were separated by agars gel electrophoresis. PCR method was used for the identification of the FII G20210A allele. An enzyme-linked immunosorbent assay (Selisa, Cambridge Life Sciences, UK) was performed to determine the antibody against ACL. Lp(a) concentration was measured using a chemical method in an Integra 700 automat (Roche Diagnostics). Homocysteine levels were determined by combined enzymatic and fluorescent polarization immune method. In this procedure, all the homocysteine content of the samples is first converted to S-adenosyl homocysteine (SAH). This product then competes with a manufacturer labeled SAH analogue for antibody binding. The amount of fluorescent analogue was measured by polarizing immune method.
###end p 25
###begin title 26
Statistical analysis
###end title 26
###begin p 27
###xml 221 222 221 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 347 349 347 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p1</italic>
###xml 358 360 358 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p2</italic>
###xml 57 65 <span type="species:ncbi:9606">patients</span>
###xml 161 169 <span type="species:ncbi:9606">Patients</span>
The homogeneous distribution of age and gender among RAO patients and control subjects was confirmed by the Mann-Whitney test and chi-squared test respectively. Patients and control subjects were compared using Student's t-test for parameters showing normal distribution, or the Mann-Whitney test when the parameters' distribution was not normal (p1 = 0.71, p2 = 0.11).
###end p 27
###begin p 28
###xml 130 131 130 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
The thrombophilic and cardiovascular risk factors were analyzed by logistic regression odds ratios with 95% confidence intervals. p-values lower than 0.05 were considered significant. The statistical analysis was performed with SPSS version 11.5 (SPSS Inc., Chicago, IL).
###end p 28
###begin title 29
Results
###end title 29
###begin p 30
###xml 180 187 176 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1-co-2-557">Table 1</xref>
###xml 42 50 <span type="species:ncbi:9606">patients</span>
The mean age of the 16 male and 12 female patients with RAO was 61.12 (+/-12.3) years, while that of the control group was 61.6 (+/-12.6) years, with a male/female ratio of 53/28 (Table 1).
###end p 30
###begin p 31
###xml 239 240 239 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 397 398 397 398 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 494 495 494 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 20 28 <span type="species:ncbi:9606">patients</span>
###xml 58 66 <span type="species:ncbi:9606">patients</span>
###xml 79 87 <span type="species:ncbi:9606">patients</span>
CRAO was seen in 20 patients, and BRAO was developed in 9 patients. In the RAO patients, logistic regression odds ratios with 95% confidence interval were compared for cardiovascular risk factor. Hypertension (OR: 3.33, 95% CI: 1.30-9.70, p = 0.014), as an average risk factor, showed significant difference, but thrombophilic risk factors such as hyperfibrinogenemia (OR: 2.9, 95% CI: 1.29-6.57, p = 0.010) and the presence of APC-resistance FV (Leiden mutation) (OR: 3.9, 95% CI: 1.43-10.96, p = 0.008) increased the chances of developing this disease.
###end p 31
###begin p 32
###xml 467 474 467 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2-co-2-557">Table 2</xref>
###xml 273 281 <span type="species:ncbi:9606">patients</span>
###xml 390 398 <span type="species:ncbi:9606">patients</span>
###xml 403 410 <span type="species:ncbi:9606">patient</span>
Statistical analysis could not be performed for other thrombophilic factors such as decrease in PC and PS activities, presence of FII 20210A allele and increase in FVIII, as thrombophilic changes could be observed in only 5 cases of those affected, and none in the control patients. In one case PC was observed, while a PS decrease was demonstrated in 2 cases, and AT were shown in 2 other patients. No patient demonstrated any difference in the F II G20210A allele (Table 2).
###end p 32
###begin p 33
Bilateral cases had not developed during the follow-up period.
###end p 33
###begin title 34
Discussion
###end title 34
###begin p 35
###xml 344 361 344 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7-co-2-557">M&#252;ller et al 1992</xref>
###xml 363 381 363 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9-co-2-557">Richard et al 1996</xref>
###xml 383 400 383 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10-co-2-557">Rumelt et al 1999</xref>
The multifactorial nature of RAO has been well documented. It may be caused by embolization from the internal carotid artery (thromboemboli or cholesterol emboli originating in atherosclerotic plaques of the carotid arteries), but rarely from the heart (eg, atrial fibrillation, aortic or mitral valve disease, endocarditis and atrial myxoma) (Muller et al 1992; Richard et al 1996; Rumelt et al 1999). The other important risk factors of RAO pathogenesis are cardiovascular risk factors such as hypertension, aortic diseases, diabetes mellitus, atherothrombosis, and current smoking.
###end p 35
###begin p 36
###xml 62 79 62 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7-co-2-557">M&#252;ller et al 1992</xref>
###xml 81 99 81 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9-co-2-557">Richard et al 1996</xref>
###xml 101 118 101 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10-co-2-557">Rumelt et al 1999</xref>
###xml 120 137 120 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8-co-2-557">Pianka et al 2000</xref>
###xml 139 157 139 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11-co-2-557">Salomon et al 2001</xref>
###xml 159 174 159 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12-co-2-557">Stojakovic 2007</xref>
###xml 462 480 462 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1-co-2-557">Ben-Ami et al 2002</xref>
Coagulation abnormalities in can play a role its development (Muller et al 1992; Richard et al 1996; Rumelt et al 1999; Pianka et al 2000; Salomon et al 2001; Stojakovic 2007). Increased coagulation may cause ischemic retinal infarction by decreased blood flow of the retinal arterioles. In some cases RAO cannot be explained with the known factors alone thus identification of other unknown risk factors such as thrombophilic risk factors should be considered (Ben-Ami et al 2002).
###end p 36
###begin p 37
###xml 0 27 0 27 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14-co-2-557">Weger and colleagues (2003)</xref>
###xml 32 60 32 60 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8-co-2-557">Pianka and colleagues (2000)</xref>
###xml 142 159 142 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15-co-2-557">Wenzel et al 1993</xref>
###xml 161 178 161 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3-co-2-557">Cahill et al 2003</xref>
###xml 180 195 180 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4-co-2-557">Chua et al 2006</xref>
###xml 205 213 <span type="species:ncbi:9606">patients</span>
###xml 381 389 <span type="species:ncbi:9606">patients</span>
Weger and colleagues (2003) and Pianka and colleagues (2000) stated that increased homocysteine level plays a role in the development of RAO (Wenzel et al 1993; Cahill et al 2003; Chua et al 2006). In our patients who suffered from RAO, we frequently found such a significant increase. No correlation was found in the methyltetrahydrofolate reductase gene polymorphism between the patients and the controls.
###end p 37
###begin p 38
###xml 0 28 0 28 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7-co-2-557">M&#252;ller and colleagues (1992)</xref>
###xml 617 634 617 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7-co-2-557">M&#252;ller et al 1992</xref>
###xml 636 657 636 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12-co-2-557">Stojakovic et al 2007</xref>
###xml 963 980 963 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7-co-2-557">M&#252;ller et al 1992</xref>
###xml 982 1003 982 1003 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12-co-2-557">Stojakovic et al 2007</xref>
###xml 692 700 <span type="species:ncbi:9606">patients</span>
Muller and colleagues (1992) proved that the increased Lp(a) level has a pathological role in the development of RAO. Elevated Lp(a) level can cause arteriosclerotic changes in small arterioles in the carotid system on one hand, and on the other hand, it is considered as a thrombophilic factor due to its antifibrinolytic effect. Lp(a) binding to plasminogen receptors in the blood vessel endothelium competitively inhibits plaminogen-plasmin transformation. High Lp(a) levels and decreased plasminogen levels have synergistic effects in further increasing thrombophilic risk when both are present at the same time (Muller et al 1992; Stojakovic et al 2007). Plasma Lp(a) levels are high in patients with central retinal artery occlusion. Elevated lipoprotein-a serum level is an established risk factor in cardiovascular and cerebrovascular diseases. It may have a role in damaging the circulation of the retinal arteries, which may lead to retinal infarction (Muller et al 1992; Stojakovic et al 2007).
###end p 38
###begin p 39
###xml 0 29 0 29 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1-co-2-557">Ben-Ami and colleagues (2002)</xref>
###xml 364 382 364 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1-co-2-557">Ben-Ami et al 2002</xref>
###xml 78 85 <span type="species:ncbi:9606">patient</span>
###xml 145 152 <span type="species:ncbi:9606">patient</span>
###xml 270 277 <span type="species:ncbi:9606">patient</span>
Ben-Ami and colleagues (2002) reported showed such case in a 19 year-old-male patient who, despite his young age, developed CRAO in one eye. The patient suffered from no cardiovascular disease and no risk factors could be shown. During the thrombophilic screening, this patient had a homozygous FV Leiden mutation and heterozygous prothombin G20210A polymorphism (Ben-Ami et al 2002).
###end p 39
###begin p 40
###xml 157 165 <span type="species:ncbi:9606">patients</span>
In the present study, we examined the importance of thrombophilic risk factors in the development of retinal artery occlusion. Our study found that the CRAO-patients have significantly in higher number a FV Leiden mutation, elevated homocysteine level and Lp(a), and our data shows that both cardiovascular and thrombophilic risk factors may have an important role in the development of RAO. Based on our data, we suggest that thrombophilia with or without the presence of vascular damage may have a key role in the development of RAO.
###end p 40
###begin p 41
###xml 237 254 237 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15-co-2-557">Wenzel et al 1993</xref>
###xml 256 273 256 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8-co-2-557">Pianka et al 2000</xref>
###xml 275 292 275 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3-co-2-557">Cahill et al 2003</xref>
###xml 294 309 294 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4-co-2-557">Chua et al 2006</xref>
###xml 432 450 432 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9-co-2-557">Richard et al 1996</xref>
###xml 452 469 452 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10-co-2-557">Rumelt et al 1999</xref>
In the case of thrombophilia, causal therapy is also available. It has been proven that cessation of smoking, in conjunction with the administration of vitamins B6, B12, and folic acid, is beneficial in the treatment of homocysteinemia (Wenzel et al 1993; Pianka et al 2000; Cahill et al 2003; Chua et al 2006). When dealing with acute fundus vascular pathology CRAO, the introduction of fibrinolytic therapy is highly recommended (Richard et al 1996; Rumelt et al 1999). Unless otherwise contraindicated, the introduction of thrombolytic therapy should be introduced within 6 hours after the onset of thrombosis. The thrombolytic therapy requires emergency room setting and professional staff. Due to the danger of heavy bleeding side effects, this treatment should not be expanded to a wider circle. It is important to find another effective therapy with lesser side effects.
###end p 41
###begin p 42
In the event that thrombophilia has been proved as existing alongside cardiovascular risk factors, we recommend antithrombotic therapy implemented together with the circulation-improving therapy. Antithrombocyte - antiplatelet therapy with salicylates may prove effective, or, if contraindicated, antiplatelet therapy per os is recommended. With this kind of therapy, the likelihood of the development of another arterial event in the other eye decreases.
###end p 42
###begin p 43
###xml 47 55 <span type="species:ncbi:9606">patients</span>
###xml 227 234 <span type="species:ncbi:9606">patient</span>
Thrombophilic screening is recommended for RAO patients under the age of 50, or with bilateral fundus vascular pathology. We recommended thrombophilic screening to other family members if RAO has occurred in the family and the patient has at least 2 strong thrombophilic factors: FV Leiden mutation, PS- or PC-decrease, etc. If cardiovascular risk factors are also present alongside thrombophilic risk factors, then chance of developing RAO gets multiplied. Positive family anamnesis after thrombophilia in selected cases raises a possibility for primary prevention with antithrombotic/antiplatelet therapy.
###end p 43
###begin title 44
References
###end title 44
###begin article-title 45
###xml 30 37 <span type="species:ncbi:9606">patient</span>
Retinal artery occlusion in a patient with factor V Leiden and prothrombin G20210A mutations
###end article-title 45
###begin article-title 46
Protein C, protein S, and antithrombin III in acute ocular occlusive diseases
###end article-title 46
###begin article-title 47
###xml 61 63 61 63 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
Meta - analysis of plasma homocysteine, serum folate, serum B12 and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease
###end article-title 47
###begin article-title 48
Homocysteine and retinal emboli: The Blue Mountains eye study
###end article-title 48
###begin article-title 49
Gerinnungsphysiologische schnell Methode zur Bestimmung des Fibrinogens
###end article-title 49
###begin article-title 50
Retinal vascular occlusion and deficiencies in the protein C pathway
###end article-title 50
###begin article-title 51
Lipoprotein (a): a risk factor for retinal vascular occlusion
###end article-title 51
###begin article-title 52
###xml 24 32 <span type="species:ncbi:9606">patients</span>
Hyperhomocysteinemia in patients with nonarteritic anterior ischemic optic neuropathy, central retinal artery occlusion, and central retinal vein occlusion
###end article-title 52
###begin article-title 53
Treatment of retinal arterial occlusion with local fibrinolysis using recombinant tissue plasminogen activator
###end article-title 53
###begin article-title 54
Aggressive systemic treatment for central retinal artery occlusion
###end article-title 54
###begin article-title 55
###xml 76 84 <span type="species:ncbi:9606">patients</span>
Thrombophilia as a cause for central and branch retinal artery occlusion in patients without an apparent embolic source
###end article-title 55
###begin article-title 56
Low density lipoprotein triglycerides and lipoprotein(a) are risk factors for retinal vascular occlusion
###end article-title 56
###begin article-title 57
Ueber Embolie der Arteria centralis retinae also Ursache plotzlichererblindung
###end article-title 57
###begin article-title 58
###xml 50 58 <span type="species:ncbi:9606">patients</span>
Role of factor V Leiden and prothrombin 20210A in patients with retinal artery occlusion
###end article-title 58
###begin article-title 59
Hyperhomocysteinemia in retinal artery and retinal vein occlusion
###end article-title 59
###begin p 60
###xml 45 53 <span type="species:ncbi:9606">patients</span>
Statistical data of retinal artery occlusion patients in cardiovascular and thrombophilic risk factors
###end p 60
###begin p 61
###xml 0 14 0 14 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Abbreviations:</bold>
Abbreviations: FVIII, factor VIII FV(Leiden), factor V of Leiden mutation; FII G20210A, factor II gene polimorphism, G20210A allele; PCdownward arrow, decreased level of proteine C; PSdownward arrow, decreased level of proteine S; plasminogen downward arrow, decreased level of plasminogen; Lipoprotein(a)upward arrow, increased level of lipoprotein(a).
###end p 61
###begin p 62
###xml 24 32 <span type="species:ncbi:9606">patients</span>
Statistical data of RAO patients by Mann-Whitney test
###end p 62
###begin p 63
###xml 0 14 0 14 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Abbreviations:</bold>
Abbreviations: FVIII, factor VIII; FV(Leiden), factor V of Leiden mutation; FII G20210A, factor II gene polimorphism, G20210A allele; PCdownward arrow, decreased level of proteine C; PSdownward arrow, decreased level of proteine S; plasminogen downward arrow, decreased level of plasminogen; Lipoprotein(a)upward arrow, increased level of lipoprotein(a).
###end p 63

